Poland· PL-100485385
Omvoh
A mirikizumab product containing mirikizumabum, registered in Poland by Eli Lilly Nederland B.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Mirikizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AC24 (mirikizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Mirikizumab · ATC L04AC24
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of mirikizumab costs, country by country.
Normalised to the WHO defined daily dose (7.1 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Mirikizumab · price per daily dose (7.1 mg)
USD · FX 28 Sept 2026
- CH Switzerland$30.99
The record
At a glance
URPL (Poland)- Active substance
- Mirikizumabum
- Manufacturer
- Eli Lilly Nederland B.V.
- Country
- Poland (PL)
- ATC code
- L04AC24
- ATC class
- Mirikizumab
- Defined daily dose
- 7.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mirikizumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandOmvoh 100 mg, solution injectable en stylo prérempliEli Lilly (Suisse) SA
- CzechiaOMVOHEli Lilly Nederland B.V., Utrecht
- United StatesOmvohEli Lilly and Company
- FinlandOmvohAbacus Medicine A/S
- BelgiumOmvoh 100 mgEli Lilly Nederland
- SwedenOmvoh 100 mg + 200 mg Injektionsvätska, lösning i förfylld injektionspennaEli Lilly Nederland B.V.
- NetherlandsOmvoh 100 mg + 200 mg oplossing voor injectie in een voorgevulde penEli Lilly Nederland B.V.
- IrelandOmvoh 100 mg solution for injection in pre-filled syringeEli Lilly Nederland B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Omvoh
- Liechtenstein · Omvoh
- Norway · Omvoh
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/771f7ca0-faac-4c8a-b01b-371aa2663891 GET /v1/drugs/771f7ca0-faac-4c8a-b01b-371aa2663891?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
"source": "urpl",
"strength": "100 mg/ml",
"packaging": "Rpz ¦ EU/1/23/1736/003 ¦ 150658\n6 amp.-strzyk. 1 ml Opakowanie zbiorcze (3 x 2 szt.)\nRpz ¦ EU/1/23/1736/002 ¦ 150659\n2 amp.-strzyk. 1 ml\nRpz ¦ EU/1/23/1736/007 ¦ 162236\n1 amp.-strzyk. 1 ml ¦ 1 amp.-strzyk. 2 ml\nRpz ¦ EU/1/23/1736/008 ¦ 162237\n6 amp.-strzyk. (3 x 2 szt.), (1 ml + 2 ml)",
"substance": "Mirikizumabum 100 mg/ml",
"common_name": "Mirikizumabum",
"pl_product_id": "100485385",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about mirikizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.